Int. J. Mol. Sci. 2013, 14(6), 12458-12483; doi:10.3390/ijms140612458
Review

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice

1,2,* email, 1,2email, 3email, 4email, 5email, 5email, 6email, 7,8,9email, 10email, 2email and 2email
Received: 17 March 2013; in revised form: 22 May 2013 / Accepted: 22 May 2013 / Published: 13 June 2013
(This article belongs to the Special Issue Advances in the Research of Melatonin)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Melatonin exerts its actions through membrane MT1/MT2 melatonin receptors, which belong to the super family of G-protein-coupled receptors consisting of the typical seven transmembrane domains. MT1 and MT2 receptors are expressed in various tissues of the body either as single ones or together. A growing literature suggests that the melatonergic system may be involved in the pathophysiology of mood and anxiety disorders. In fact, some core symptoms of depression show disturbance of the circadian rhythm in their clinical expression, such as diurnal mood and other symptomatic variation, or are closely linked to circadian system functioning, such as sleep-wake cycle alterations. In addition, alterations have been described in the circadian rhythms of several biological markers in depressed patients. Therefore, there is interest in developing antidepressants that have a chronobiotic effect (i.e., treatment of circadian rhythm disorders). As melatonin produces chronobiotic effects, efforts have been aimed at developing agomelatine, an antidepressant with melatonin agonist activity. The present paper reviews the role of the melatonergic system in the pathophysiology of mood and anxiety disorders and the clinical characteristics of agomelatine. Implications of agomelatine in “real world” clinical practice will be also discussed.
Keywords: melatonin; melatonergic receptors; serotonin; dopamine; noradrenaline; agomelatine; major depression; anxiety
PDF Full-text Download PDF Full-Text [279 KB, uploaded 19 June 2014 04:56 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

De Berardis, D.; Marini, S.; Fornaro, M.; Srinivasan, V.; Iasevoli, F.; Tomasetti, C.; Valchera, A.; Perna, G.; Quera-Salva, M.-A.; Martinotti, G.; di Giannantonio, M. The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. Int. J. Mol. Sci. 2013, 14, 12458-12483.

AMA Style

De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva M-A, Martinotti G, di Giannantonio M. The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. International Journal of Molecular Sciences. 2013; 14(6):12458-12483.

Chicago/Turabian Style

De Berardis, Domenico; Marini, Stefano; Fornaro, Michele; Srinivasan, Venkataramanujam; Iasevoli, Felice; Tomasetti, Carmine; Valchera, Alessandro; Perna, Giampaolo; Quera-Salva, Maria-Antonia; Martinotti, Giovanni; di Giannantonio, Massimo. 2013. "The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice." Int. J. Mol. Sci. 14, no. 6: 12458-12483.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert